Cepheid Story Overview

CPHD -- USA Stock  

null 52.95  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for Cepheid. But even though we do not provide professional-grade financial sentiment analysis on Cepheid, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Cepheid. Check also Trending Equities.
Exercise or conversion by David Persing of 3 shares of Cepheid subject to Rule 16b-3
Filed transaction by Cepheid director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Cepheid insider trading alert for exercise of common stock by David Persing, Exec VPChief MedTech Officer, on October 7, 2017. This event was filed by Cepheid with SEC on 2011-11-01. SEC Form: Changes in beneficial ownership. David Persing is currently serves as executive vice president chief medical and technology officer, director of Cepheid

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for Cepheid

few hours ago at http://thestockanalysis.com 
Global Biochips Market Sales, Leading Player, Application Forecast to 2025
news
Stock AnalysisFull coverage
3 days ago at www.macroaxis.com 
Acquisition by Thomas Brown of 460 shares of Cepheid subject to Rule 16b-3
Macroaxis News
Filed transaction by Cepheid director. Grant, award or other acquisition pursuant to Rule 16b-3
six days ago at http://thestockanalysis.com 
Global and China Cervical Cancer Diagnostic Tests Market 2018 Healthcare and Clinical Reviews by Expert 2023
news
Stock AnalysisFull coverage
over a week ago at http://registrarjournal.com 
Danaher Downgraded to Hold at Zacks Investment Research
news
registrarjournal.comFull coverage
over a week ago at www.macroaxis.com 
Sale by Thomas Gutshall of 1657 shares of Cepheid
Macroaxis News
Filed transaction by Cepheid director. General open market or private sale of non-derivative or derivative security
over two weeks ago at http://ledgergazette.com 
Danaher Cut to Hold at Zacks Investment Research
news
The Ledger GazetteDanaher Rating Increased to Buy at Zacks Investment Research Week HeraldSEC FORM 4 - SEC.gov SEC.govFull coverage
over three weeks ago at www.macroaxis.com 
Exercise or conversion by Glenn Steele of 1050 shares of Cepheid subject to Rule 16b-3
Macroaxis News
Filed transaction by Cepheid director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://bangaloreweekly.com 
Cepheids Hold Rating Restated at Canaccord Genuity
news
BangaloreWeeklyFull coverage
over a month ago at http://www.nasdaq.com 
The Zacks Analyst Blog Highlights Mastercard, NVIDIA, Danaher, Automatic Data Processing and Altria
nasdaq News
NasdaqFull coverage
over a month ago at http://thetechnicalprogress.com 
Exercise or conversion by Cristina Kepner of 1050 shares of Cepheid subject to Rule 16b-3
news
Filed transaction by Cepheid director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://www.streetinsider.com 
OpGen Presents Acuitas Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug ...
Street Insider News
StreetInsider.comFull coverage
over three months ago at http://heraldks.com 
Exercise or conversion by Reyes Humberto of 313 shares of Cepheid subject to Rule 16b-3
news
Filed transaction by Cepheid officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three months ago at http://ledgergazette.com 
Cepheid Given Daily Media Sentiment Rating of 0.16
news
The Ledger Gazette - Dec 26, 2017 Cepheid logo Headlines about Cepheid have been trending somewhat positive this week, according to Accern Sentiment Analysis.

Did you try this?

Run Global Markets Map Now
   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Global Markets Map

Earnings Per Share

Earnings Per Share Comparative Analysis
Cepheid is currently under evaluation in earnings per share category among related companies. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Peers

Cepheid Related Equities
EYPT  2.56 %   
0%
100.0%
EXFO  1.56 %   
0%
60.0%
IR  0.99 %   
0%
38.0%
FARO  0.56 %   
0%
21.0%
VSUL  0.33 %   
0%
13.0%
WGBS  0.00 %   
0%
0%
A  0.4 %   
15.0%
0%
ELSE  0.75 %   
29.0%
0%
ST  1.18 %   
45.0%
0%
FEIM  1.73 %   
67.0%
0%
Check also Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.